Solid Tumors30

实体瘤30

• 批准号: 6558383
• 负责人: LEE J. HELMAN
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6558383
• 关键词: Ewing's tumor; T lymphocyte; alkylating agents; binding proteins; bioimaging /biomedical imaging; clinical research; colony stimulating factor; combination cancer therapy; cytotoxicity; dosage; human subject; human therapy evaluation; insulinlike growth factor; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; osteosarcoma; patient oriented research; rhabdomyosarcoma; sarcoma; somatostatin; stem cells; tamoxifen

We completed a study of the long acting somatostatin, OncoLar, in recurrent osteosarcoma. Briefly, the data demonstrate a 50% reduction in circulating IGFI levels with no changes in IGFBP3 levels or IGFII levels, and no further IGFI reduction with the addition of tamoxifen. No objective responses were seen. This study was recently submitted and accepted for publication. We have continued to accrue patients on a study for newly diagnosed localized and metastatic osteosarcoma patients in collaboration with several other centers. This study will attempt to determine the value of various new imaging techniques in predicting response to neoadjuvant chemotherapy as well as to prospectively perform gene expression profiling analysis on all tumors. It will also pilot the application of high-dose alkylating agent therapy with peripheral stem cell rescue for all metastatic and recurrent, as well as patients and patients who demonstrate a poor histologic response to standard neoadjuvant therapy. We have begun a study for newly diagnosed sarcoma patients to evaluate the effectiveness of a long acting G-CSF compound. Patients receive standard chemotherapy and are randomized to standard or long-acting G-CSF. I have also recently been asked to Chair the Children's Oncology Group Ewing's Sarcoma Biology Study. This protocol has been written and is currently in review at the COG operations office, It is anticipated to open in early 2002.

我们在复发性骨肉瘤中完成了一项对长作用生长抑素的研究。简而言之，数据表明循环IGFI水平降低了50％，而IGFBP3水平或IGFII水平没有变化，并且加入他莫昔芬没有进一步的IGFI降低。没有看到客观的反应。这项研究最近被提交并接受了出版。我们继续为新诊断的局部和转移性骨肉瘤患者与其他几个中心合作，继续为患者累积患者。这项研究将尝试确定各种新成像技术在预测对新辅助化疗的反应以及对所有肿瘤上的基因表达分析分析中的价值。它还将通过所有转移性和经常性的外周干细胞救援高剂量烷基化剂治疗以及对标准新辅助治疗的组织学反应不佳的患者以及患者的应用。 我们已经开始针对新诊断的肉瘤患者的研究，以评估长作用G-CSF化合物的有效性。患者接受标准化疗，并随机分配给标准或长效G-CSF。 最近，我还被要求主持儿童肿瘤学集团尤因的肉瘤生物学研究。该协议已编写，目前正在COG运营办公室进行审查，预计该协议将于2002年初开放。